GlassScriptPhysician profile
Inga Zilberstein
NPI 1659459089
$6,751.77
in general payments reported to CMS, 2019-2025
27 companies · $840 in 2025
The $840 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $441 · 2021: $823 · 2022: $1,607 · 2023: $1,110 · 2024: $845 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.20 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.80 | 2019-2023 | Lo Loestrin Fe, Liletta, Orilissa |
| Astellas Pharma US INC | $865.13 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $629.90 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $477.49 | 2021-2023 | Balcoltra |
| Therapeuticsmd, INC. | $404.54 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $311.48 | 2019-2025 | |
| Myovant Sciences INC. | $238.13 | 2021-2022 | |
| Shield Therapeutics INC | $237.23 | 2024-2025 | |
| Agile Therapeutics, INC. | $205.75 | 2022-2024 | Twirla |
| Millicent US INC | $200.39 | 2024-2025 | Intrarosa, Femlyv |
| Evofem Biosciences, INC. | $193.83 | 2020-2024 | Phexxi |
| Pfizer INC. | $181.95 | 2019-2024 | |
| Vertical Pharmaceuticals, LLC | $174.81 | 2019 | |
| Scynexis, INC. | $172.23 | 2022 | |
| Coopersurgical, INC. | $160.21 | 2020-2024 | Paragard T 380a, Paragard T 380a |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $131.51 | 2019-2020 | |
| Mission Pharmacal Company | $113.78 | 2019-2020 | |
| Janssen Biotech, INC. | $91.60 | 2019-2022 | |
| Amgen INC. | $87.62 | 2019-2020 | |
| Organon LLC | $73.25 | 2021-2023 | Nexplanon |
| Exeltis, USA INC. | $67.86 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $63.64 | 2019-2021 | |
| Allergan, INC. | $62.99 | 2019-2020 | |
| Lupin INC. | $55.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.54 | 2019 | |
| Dexcom, INC. | $21.30 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $18.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inga Zilberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.